MiraVista Diagnostics Lateral Flow Assay | Lab Animation

Smartphone readers with patented image processing technology can quantify lateral flow test results by dynamically assessing image quality, focus, lighting, and orientation, eliminating the need for expensive dedicated readers while enabling data recording, location capture, barcode traceability, and automatic sharing through the phone's connectivity.

Cell phone cameras equipped with simple optics can provide quantitative readout for paper-based assays. Image analysis software identifies fiducial marks, locates assay spots, and measures intensity over time. Initial rate measurements provide quantitative concentration information across multiple orders of magnitude, enabling sophisticated diagnostics with minimal instrumentation.

Lateral flow testing technology has evolved beyond simple yes/no devices for single biomarkers to multiplexed capabilities that can test for multiple biomarkers simultaneously. The technology can now quantify results rather than just providing binary outcomes, using small readers or smartphone apps for measurement. The tests can work with multiple sample matrices including saliva, urine, and blood. Various chemistry formats and particle types can be used to generate signals, with common examples being pink (gold) and blue (latex) color indicators.

Lateral flow immunoassays, exemplified by pregnancy tests, represent the most common paper-based diagnostic technology. These binary tests work well for conditions with clear yes/no outcomes but are limited for quantitative analysis. Wax printer technology enables mass production of paper-based diagnostic devices by printing wax patterns onto paper, which absorb when heated. These printers cost approximately $800 and can produce about 10 million tests per year when operating 24 hours daily. The printing process takes about two seconds per device. Smartphone camera phones can capture images of paper-based diagnostic devices, which are then sent to central laboratories for analysis. This approach eliminates the need for doctors to be present at the point of care, allowing healthcare workers to collect samples and transmit data while computers perform complex analysis.

Commercial rapid diagnostic tests (like pregnancy tests) use antibody-based assays that produce visible lines when positive. A smartphone-based optical reader replaces expensive laboratory equipment ($20,000-$50,000) by using the phone's camera and computational power. Optimized angled detection with custom amplification achieved one order of magnitude better limit of detection compared to standalone laboratory readers.

In radioligand binding assays, specific binding refers to the tight, high-affinity interaction between a ligand and its target receptor, while non-specific binding occurs at low-affinity sites throughout the reaction mixture; these two types of binding can be separated by adding excess unlabeled (cold) ligand, which displaces the radioactive (hot) ligand from specific sites but not from non-specific sites, allowing researchers to calculate specific binding by subtracting non-specific binding from total binding and construct saturation curves to determine binding affinity through the dissociation constant (Kd), which equals the ligand concentration at which half of the receptors are bound.

This webinar addresses common performance issues in solid-phase immunoassays (ELISA, lateral flow, beads, ELISPOT) including signal variability, excessive background, and poor dose response, explaining that these problems often stem from improper plate coating (antibodies not oriented correctly, incorrect coating concentration causing hook effects), inadequate blocking (non-specific binding, cross-reactivity), and unstable reagents (denatured enzymes, degraded proteins). The presentation emphasizes that successful assay development requires understanding the fundamental principles of antibody-antigen interactions, proper solid support utilization, and careful optimization of coating buffers, blocking agents, and stabilization protocols to achieve consistent, reliable results.

The hook effect is a phenomenon in one-step sandwich ELISA where high analyte concentrations produce falsely low results due to saturation of capture antibody binding sites, which prevents sufficient detector antibody binding to the antigen-antibody complex; this can be identified by comparing undiluted and diluted samples (where diluted samples show higher concentrations) and corrected by performing serial dilutions and multiplying the concentration by the dilution factor.

Hormone laboratories use immunological assays (antigen-antibody reactions) and chromatography-mass spectrometry. Immunological assays include chemiluminescence methods with significant platform variability due to different antibodies, epitopes, and designs. Two-step sandwich assays with wash steps reduce hook effect risk, while one-step assays lack this protection. The hook effect occurs when excess analyte prevents both capture and detection antibodies from binding the same antigen molecule, causing falsely low results. Biotin interferes with assays using biotin-streptavidin reactions, causing falsely low results in sandwich assays and falsely high in competitive assays. Heterophilic antibodies are non-specific antibodies binding assay reagents, causing falsely positive results in sandwich assays. They are present in up to 30% of the population, with interference in 2-3% of tests. When results are incompatible with clinical presentation, the laboratory can: compare with different assays, test linearity by serial dilution, precipitate with PEG to remove large molecules, or use heterophilic antibody blocking reagents.

Lateral flow tests compared to laboratory methods (ELISA, chemiluminescence) show: (1) Lower sensitivity but higher specificity in some tests, (2) Faster results but less quantitative information, (3) Greater accessibility but more potential for human error, and (4) Lower cost but potentially lower accuracy. The choice of test method should be based on the intended application, available resources, and required accuracy.

Rapid diagnostic tests (lateral flow assays) provide qualitative results with turnaround time of just minutes, medium throughput (one patient per test), and are meant for point-of-care use. ELISA assays can be qualitative or semi/fully quantitative, take a couple of hours, have medium throughput (several hundred per day), and are lab-based. Chemiluminescent assays provide qualitative or quantitative results, can be as fast as 18 minutes (Roche assay), have high throughput (up to thousands per day), and are lab-based. Neutralization assays are quantitative tests requiring days to complete, very low throughput (only several per day), and are reference lab-based requiring biosafety level 3 containment procedures. Only neutralization assays actually test for antibody function, making them considered gold standards.

Initial comparisons between lateral flow tests and PCR tests appeared to show low sensitivity (around 40%) because they compared fundamentally different tests—PCR detects persistent genetic material while lateral flow detects active viral proteins present only during infectious periods. Proper comparison reveals lateral flow tests achieve above 80 per cent sensitivity and potentially 95 per cent for detecting infectious individuals. For public health purposes, lateral flow tests are more reliable than direct PCR comparisons suggested. PCR tests remain essential for variant sequencing and clinical certainty but should not replace lateral flow for routine monitoring.

Lateral flow assays can be used for both serology (antibody) testing and antigen testing, as well as detecting chemical and biological markers. The technology is scalable globally with manufacturers in Taiwan, India, Brazil, and the US. A universal lateral flow assay reader standardizes tests, improves sensitivity, eliminates human error, and collects metadata including vaccination status and disease history. The reading of each assay takes approximately 1-2 seconds, with machines capable of processing 500 samples per hour. Quantitative lateral flow assays can be developed by calibrating against PCR or ELISA results. Nucleocapsid antibodies are the best candidate for serology testing because they are completely discriminative between natural infection and vaccination. The nucleocapsid protein is more stable and does not mutate like spike, making it a reliable marker for natural immunity. Finger prick tests are not sensitive enough; venous blood draw is required.

PCR tests are more accurate laboratory-based tests that detect the presence of the COVID-19 virus and are primarily used for symptomatic individuals, while lateral flow tests are rapid antigen tests that can be done at home and are suitable for asymptomatic screening; PCR tests require laboratory processing and take up to 3 days for results, whereas lateral flow tests provide results in about 30 minutes, and PCR tests are typically required for hospital procedures, care home staff, and international travel, while lateral flow tests are free and can be ordered online or picked up from test collection sites.